结核分枝杆菌耐氯法齐明相关基因研究进展  

Progress on Drug Resistance Related Genes of Mycobacterium Tuberculosis to Clofazimine

作　　者：刘柏杉 贺仁忠[1] LIU Bai-shan;HE Renzhong(The Second Department of Respiratory Medicine,the Affiliated Hospital of Zunyi Medical College,Zunyi 563003,China)

机构地区：[1]遵义医学院附属医院呼吸二科,贵州省遵义市563003

出　　处：《实用心脑肺血管病杂志》2018年第11期21-24,共4页Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease

基　　金：国家自然科学基金资助项目(81760003)

摘　　要：目前,全球范围内结核病防控形势仍十分严峻,且耐药结核病所占比例较高,因此不断有新型抗结核病药物被研发出来并应用于临床。氯法齐明是目前世界卫生组织(WHO)推荐的二线核心抗结核药物之一,主要用于治疗耐多药结核病(MDR-TB)且疗效肯定,但近年来结核分枝杆菌对氯法齐明耐药现象增多。本文综述了结核分枝杆菌耐氯法齐明相关基因,旨在为结核分枝杆菌对氯法齐明的耐药机制研究提供参考。Tuberculosis prevention and control situation is still serious all of the world at present,and proportion of drug resistant tuberculosis is relatively high,thus new anti-tuberculosis drugs are being continually developed and applied on clinic.Clofazimine is one of second-line core anti-tuberculosis drugs in treating MDR-TB recommended by WHO,but drug resistance to clofazimine gradually increased in recent years.This paper reviewed the drug resistance related genes of Mycobacterium tuberculosis to clofazimine,in order to provide a reference for the research on resistance mechanism to clofazimine.

关 键 词：结核分枝杆菌 结核 抗多种药物性 广泛耐药结核 氯法齐明 基因 突变 综述 

分 类 号：R378.911[医药卫生—病原生物学] R394.2[医药卫生—基础医学]